NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, ...

Novavax cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of ...

A clinical trial has found that Novavax’ COVID-19 vaccine is 86% protective against the UK variant of SARS-CoV-2, only slightly lower than the 96% efficacy seen with the original strain of the ...

Indian retailer Nykaa reported a 72% rise in its second-quarter profit on Tuesday as its mainstay beauty products segment ...

Italy's largest bank Intesa Sanpaolo said it would partner with BlackRock , the world's biggest asset manager and a leading Intesa shareholder, to offer digital wealth management services to clients ...

At the European Society of Cardiology, Coventry Hospital in the UK presented data on the use of VIVO in very ... Global Clingwrap Machine Market was... Novavax, Inc. , a global company advancing ...

Novavax Inc is a clinical-stage vaccine company. It is engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.

J.P. Morgan analyst Eric Joseph maintained a Sell rating on Novavax (NVAX – Research Report) yesterday and set a price target of $9.00. Eric Joseph has given his Sell rating due to a combination of ...

Novavax ( (NVAX)) has released its Q3 earnings. Here is a breakdown of the information Novavax presented to its investors. Novavax, Inc., based in Gaithersburg, Maryland, is a global biotechnology ...

NovaVax Inc.’s stock NVAX tumbled 7% early Tuesday, after the company cut its full-year guidance, offsetting a narrower-than-expected third-quarter loss and better-than-expected revenue. The company ...

The US Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug (IND) application for ...